HC Wainwright Reduces Earnings Estimates for Vor Biopharma

Key Points

• HC Wainwright has revised Vor Biopharma's FY2028 earnings per share estimate down to $0.03, lowering it from a previous estimate of $0.05, while maintaining a "Buy" rating with a target price of $3.00.
• Vor Biopharma's stock has experienced significant activity, trading up 5.3% to $2.09 recently, with a market capitalization of $264.04 million.
• Institutional investors hold a substantial 97.29% of the company's stock, reflecting strong interest from major investment firms like Goldman Sachs and Jane Street Group.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities researchers at HC Wainwright reduced their FY2028 EPS estimates for shares of Vor Biopharma in a research note issued on Thursday, August 14th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.03 per share for the year, down from their prior forecast of $0.05. HC Wainwright has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's FY2029 earnings at $0.21 EPS.

A number of other equities analysts have also issued reports on VOR. Jones Trading lowered shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. JMP Securities reaffirmed a "market perform" rating and issued a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Citizens Jmp cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 9th. Finally, Baird R W cut shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.07.

Vor Biopharma Trading Up 7.3%

VOR traded up $0.15 on Friday, reaching $2.20. The company had a trading volume of 6,022,896 shares, compared to its average volume of 7,952,958. The company has a fifty day moving average of $1.66 and a 200-day moving average of $1.05. The company has a market capitalization of $278.70 million, a P/E ratio of -1.33 and a beta of 2.06. Vor Biopharma has a one year low of $0.13 and a one year high of $3.29.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently made changes to their positions in VOR. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company's stock worth $44,007,000 after purchasing an additional 16,897,159 shares in the last quarter. Lynx1 Capital Management LP purchased a new stake in shares of Vor Biopharma in the fourth quarter worth approximately $707,000. Jane Street Group LLC purchased a new stake in shares of Vor Biopharma in the first quarter worth approximately $140,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Vor Biopharma in the first quarter worth approximately $100,000. Finally, Trustees of Columbia University in the City of New York purchased a new stake in shares of Vor Biopharma in the fourth quarter worth approximately $102,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.